[go: up one dir, main page]

DE69523295D1 - NASAL AND Ocular use of ketamine for pain control and detoxification - Google Patents

NASAL AND Ocular use of ketamine for pain control and detoxification

Info

Publication number
DE69523295D1
DE69523295D1 DE69523295T DE69523295T DE69523295D1 DE 69523295 D1 DE69523295 D1 DE 69523295D1 DE 69523295 T DE69523295 T DE 69523295T DE 69523295 T DE69523295 T DE 69523295T DE 69523295 D1 DE69523295 D1 DE 69523295D1
Authority
DE
Germany
Prior art keywords
ketamine
nasal
detoxification
pain control
ocular use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69523295T
Other languages
German (de)
Other versions
DE69523295T2 (en
Inventor
Stuart L Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69523295D1 publication Critical patent/DE69523295D1/en
Application granted granted Critical
Publication of DE69523295T2 publication Critical patent/DE69523295T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to self-management of pain on an outpatient basis comprising administering via a nasal route a dose of ketamine effective to alleviate pain to a subject suffering from pain.
DE69523295T 1994-02-25 1995-02-24 NASAL AND Ocular use of ketamine for pain control and detoxification Expired - Lifetime DE69523295T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain
PCT/US1995/002418 WO1995022965A2 (en) 1994-02-25 1995-02-24 Nasal and ocular administration of ketamine to manage pain and for detoxification

Publications (2)

Publication Number Publication Date
DE69523295D1 true DE69523295D1 (en) 2001-11-22
DE69523295T2 DE69523295T2 (en) 2002-07-11

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523295T Expired - Lifetime DE69523295T2 (en) 1994-02-25 1995-02-24 NASAL AND Ocular use of ketamine for pain control and detoxification

Country Status (11)

Country Link
US (1) US5543434A (en)
EP (1) EP0751766B1 (en)
JP (1) JP4729148B2 (en)
AT (1) ATE206913T1 (en)
CA (1) CA2184077C (en)
DE (1) DE69523295T2 (en)
DK (1) DK0751766T3 (en)
ES (1) ES2165910T3 (en)
MX (1) MX9603633A (en)
PT (1) PT751766E (en)
WO (1) WO1995022965A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
CA2213567C (en) * 1995-02-24 2010-01-26 Stuart L. Weg Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (en) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
US6948492B2 (en) * 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2641760A1 (en) 2001-05-24 2002-11-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
PL208484B1 (en) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
CN1551770A (en) 2001-07-06 2004-12-01 ������ҩ�����޹�˾ Oxymorphone controlled-release formulation
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003051367A1 (en) * 2001-12-18 2003-06-26 Alexza Molecular Delivery Corporation Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
EP1625335A2 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
JP2007509115A (en) * 2003-10-21 2007-04-12 ソセイ・アール・アンド・ディー・リミテッド Use of non-opiates for opiate augmentation
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2576961A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
CN101466364A (en) 2006-03-22 2009-06-24 纽约大学西奈山医学院 Intranasal administration of ketamine to treat depression
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
BR112015003796A2 (en) * 2012-08-23 2017-07-04 L Weg Stuart anxiolytic composition, formulation and method of use
CN111643449A (en) 2013-03-15 2020-09-11 詹森药业有限公司 Pharmaceutical composition of S-ketamine hydrochloride
JP6462663B2 (en) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ Methods for treating post-traumatic stress disorder
HRP20211629T1 (en) 2013-09-13 2022-02-04 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
MA40620A (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET GENOTYPE SPECIFIC DOSAGE REGIMES (SNP RS6265) AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US9918993B2 (en) * 2015-06-19 2018-03-20 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for anesthesiological applications
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (en) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 Esketamine for the treatment of depression
KR102852740B1 (en) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. Electrical Condensation Aerosol Device
CN111936127A (en) 2018-02-15 2020-11-13 国立大学法人千叶大学 Agent for preventing or treating inflammatory disease or bone disease, and pharmaceutical composition
CN112533595A (en) 2018-05-04 2021-03-19 感知神经科学公司 Method for treating substance abuse
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. ESKETAMIN USED TO TREAT DEPRESSION
WO2020240279A1 (en) 2019-05-31 2020-12-03 Lionheart Pharmaceuticals Aps Intranasal administration of ketamine to cluster headache patients
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
IL294485A (en) 2020-01-22 2022-09-01 Seelos Therapeutics Inc Reducing side effects of nmda antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
WO1995022965A2 (en) 1995-08-31
ES2165910T3 (en) 2002-04-01
JPH10500664A (en) 1998-01-20
CA2184077C (en) 2007-12-11
US5543434A (en) 1996-08-06
MX9603633A (en) 1998-01-31
PT751766E (en) 2002-04-29
EP0751766A1 (en) 1997-01-08
DK0751766T3 (en) 2002-02-11
CA2184077A1 (en) 1995-08-31
JP4729148B2 (en) 2011-07-20
DE69523295T2 (en) 2002-07-11
EP0751766B1 (en) 2001-10-17
ATE206913T1 (en) 2001-11-15
WO1995022965A3 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
DE69523295D1 (en) NASAL AND Ocular use of ketamine for pain control and detoxification
NO20101190L (en) Use of buprenorphine in the manufacture of a medicament
DE69600307D1 (en) Respirator for the treatment of respiratory insufficiency
DE69528247D1 (en) Regulation of water treatment agent dosage, based on operating system voltages
DE59300964D1 (en) CONTROL DEVICE FOR THE AIR PRESSURE OF AIR TIRED VEHICLE WHEELS.
DE69521521D1 (en) MONO- OR POLY-FUNCTIONAL CONJUGATES OF POLYLYSINE
DE58902094D1 (en) COMBINATION DEVICE FOR THE TREATMENT OF NERVOUS AND NERVE FIBER DISEASES AND INJURIES.
DE69609868D1 (en) NEW STEROIDESTERS FOR TREATING SKIN DISEASES
DE69630947D1 (en) PAIN TREATMENT AGENTS
DE122005000043I1 (en) Compositions for achieving analgesia and inhibiting the progression of neuropathic pain disorders
ATE227127T1 (en) HIGH DOSE CHROME TRIPICOLINATE FOR THE TREATMENT OF TYPE II DIABETES
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
FI972308A0 (en) 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions containing them and methods for their use
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
ATE297396T1 (en) NEW ATROPISOMERS OF 2,3-DISUBSTITUTED-(5,6)-HETEROARYLCONDENSED-PYRIMIDINE-4-ONENES
DE59806627D1 (en) ARYLSULFONAMIDES AND ANALOGS AND THEIR USE FOR TREATING NEURODEGENERATIVE DISEASES
DZ1988A1 (en) Combination therapy for the treatment of winter.
LV11940A (en) The use of melatonin for the treatment of people who are dependent on grass
DE69910425D1 (en) NEW THERAPEUTIC USE OF NICERGOLINE
ATE307600T1 (en) USE OF MYCOBACTERIUM VACCAE FOR THE THERAPY OF CHRONIC FATIGUE SYNDROME
NO990450D0 (en) Treatment of mental disorders
IS1919B (en) Benzamide for the treatment of neurodegenerative disorders
PT869785E (en) 4-HYDROXYCUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS NOT INSULINODEPENDENT
ATE218866T1 (en) COMBINATION THERAPY FOR THE TREATMENT OF AIDS
FI953622L (en) Use of ifenprodil and its diastereoisomers for the preparation of medicaments useful for the treatment of peripheral neuropathic conditions and degenerative diseases of the central nervous system

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN